10,227 Shares in OraSure Technologies, Inc. (NASDAQ:OSUR) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new position in OraSure Technologies, Inc. (NASDAQ:OSUR) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 10,227 shares of the medical instruments supplier’s stock, valued at approximately $37,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Peapod Lane Capital LLC acquired a new position in shares of OraSure Technologies in the fourth quarter worth about $1,730,000. Barclays PLC increased its holdings in OraSure Technologies by 182.6% during the 3rd quarter. Barclays PLC now owns 195,793 shares of the medical instruments supplier’s stock worth $836,000 after purchasing an additional 126,503 shares during the last quarter. Exchange Traded Concepts LLC acquired a new position in shares of OraSure Technologies in the 4th quarter valued at approximately $287,000. Franklin Resources Inc. boosted its stake in shares of OraSure Technologies by 28.5% during the 3rd quarter. Franklin Resources Inc. now owns 269,269 shares of the medical instruments supplier’s stock valued at $1,091,000 after buying an additional 59,723 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of OraSure Technologies in the fourth quarter worth $205,000. 93.50% of the stock is owned by hedge funds and other institutional investors.

OraSure Technologies Stock Down 0.3 %

NASDAQ:OSUR opened at $2.93 on Monday. The company has a market cap of $219.16 million, a PE ratio of 19.53 and a beta of 0.76. The business’s 50 day moving average is $3.49 and its two-hundred day moving average is $3.78. OraSure Technologies, Inc. has a 52 week low of $2.69 and a 52 week high of $5.59.

OraSure Technologies announced that its Board of Directors has authorized a stock buyback plan on Monday, March 24th that permits the company to repurchase $40.00 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to purchase up to 15.6% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

Separately, StockNews.com downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th.

Insiders Place Their Bets

In related news, CFO Kenneth J. Mcgrath bought 64,000 shares of the company’s stock in a transaction on Thursday, February 27th. The shares were purchased at an average cost of $3.15 per share, with a total value of $201,600.00. Following the completion of the transaction, the chief financial officer now directly owns 371,013 shares of the company’s stock, valued at approximately $1,168,690.95. This represents a 20.85 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Manner Carrie Eglinton bought 78,625 shares of the business’s stock in a transaction on Thursday, February 27th. The stock was bought at an average price of $3.15 per share, for a total transaction of $247,668.75. Following the completion of the purchase, the chief executive officer now directly owns 1,259,664 shares of the company’s stock, valued at $3,967,941.60. The trade was a 6.66 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 190,284 shares of company stock valued at $600,348. Company insiders own 3.40% of the company’s stock.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.